SCM
ANAB icon

Soleus Capital Management’s AnaptysBio ANAB Stock Holding History

Soleus Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,000
Closed -$333K – 98
2026
Q1 		$333K Sell
6,000
-129,000
-96% -$6.94M 0.01% 87
2025
Q4 		$6.54M Sell
135,000
-491,040
-78% -$19.1M 0.24% 61
2025
Q3 		$19.2M Buy
626,040
+305,000
+95% +$7M 0.97% 29
2025
Q2 		$7.13M Buy
321,040
+218,988
+215% +$4.58M 0.47% 47
2025
Q1 		$1.9M Sell
102,052
-311,948
-75% -$5.2M 0.14% 63
2024
Q4 		$5.48M Buy
+414,000
New +$10M 0.34% 52
2023
Q1 		– Sell
-14,727
Closed -$456K – 78
2022
Q4 		$456K Sell
14,727
-49,300
-77% -$1.39M 0.07% 69
2022
Q3 		$1.63M Sell
64,027
-579,548
-90% -$13.6M 0.22% 60
2022
Q2 		$13.1M Buy
+643,575
New +$14.3M 2.04% 14

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Soleus Capital Management's ANAB Position: Q2 2026 in Review

Soleus Capital Management sold out of AnaptysBio (ANAB) in Q2 2026, closing a stake of 6,000 shares — an estimated $333K sold.

Soleus Capital Management first reported a position in ANAB in Q2 2022 and held it in 9 quarters. The position peaked at $19.2M in Q3 2025. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Soleus Capital Management reported no remaining AnaptysBio position as of Q2 2026 after selling out during the quarter.
  • Soleus Capital Management sold 6,000 AnaptysBio shares in Q2 2026, an estimated $333K.
  • Soleus Capital Management first reported a position in AnaptysBio in Q2 2022 and held it in 9 quarters.
  • Soleus Capital Management's AnaptysBio position peaked at $19.2M in Q3 2025.
  • 213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.